Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Larry A. Mole"'
Publikováno v:
Hepatology. 66:27-36
Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected individuals receiving direct-acting antiviral (DAA) therapy. The overall risk among patients with current or prior HBV infection in the context of DAA treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849c87250faf832ed78d4e85f86c7da7
https://doi.org/10.1002/hep.29135
https://doi.org/10.1002/hep.29135
Autor:
Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus, Debika Bhattacharya, Timothy P. Loomis, Pamela S. Belperio, Matthew Bidwell Goetz
Publikováno v:
Clinical Infectious Diseases. 64:1711-1720
Author(s): Bhattacharya, Debika; Belperio, Pamela S; Shahoumian, Troy A; Loomis, Timothy P; Goetz, Matthew B; Mole, Larry A; Backus, Lisa I | Abstract: Background.Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17621b8c6d5514b58f10d077b362b6b5
https://doi.org/10.1093/cid/cix111
https://doi.org/10.1093/cid/cix111
Publikováno v:
Alimentary Pharmacology & Therapeutics. 44:400-410
Real-world data are needed to inform hepatitis C virus (HCV) treatment decisions.To assess the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ± RBV) vs. ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in genotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d602fa0fa130c25d6f75871f1af89bd
https://doi.org/10.1111/apt.13696
https://doi.org/10.1111/apt.13696
Publikováno v:
Hepatology. 64:405-414
Real-world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions. The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been rapid, but variations often occur in clinical practice. The ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3511a356c524663dc8722fc9eae1fe
https://doi.org/10.1002/hep.28625
https://doi.org/10.1002/hep.28625
Publikováno v:
Journal of hepatology. 70(1)
Background & Aim Understanding the real-world effectiveness of all-oral hepatitis C virus (HCV) regimens informs treatment decisions. We evaluated the effectiveness of daclatasvir + sofosbuvir ± ribavirin (DCV + SOF ± RBV) and velpatasvir/sofosbuvi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3435ccf3e63a4dfb1cd26f2e84307e
https://pubmed.ncbi.nlm.nih.gov/30266283
https://pubmed.ncbi.nlm.nih.gov/30266283
Publikováno v:
Alimentary Pharmacology & Therapeutics. 42:559-573
Real-world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions.To assess sustained virological response (SVR) of sofosbuvir (SOF)-based regimens in routine medical practice.Observational, intent-to-treat cohort analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4c99bce43f4a3f35971c4e90d610e7
https://doi.org/10.1111/apt.13300
https://doi.org/10.1111/apt.13300
Publikováno v:
Journal of Clinical Gastroenterology. 49:329-335
To examine the effect of provider type on outcomes and safety in a large hepatitis C virus (HCV)-infected cohort treated in routine medical practice.Nonphysician providers (NPP) are uniquely positioned to expand health care infrastructure to meet HCV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682f18c0f8e48491c09db99c201ca3ef
https://doi.org/10.1097/mcg.0000000000000124
https://doi.org/10.1097/mcg.0000000000000124
Publikováno v:
Hepatology (Baltimore, Md.). 68(3)
The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91bbfc6d5ac4d740d6d67f38bc6351df
https://pubmed.ncbi.nlm.nih.gov/29514390
https://pubmed.ncbi.nlm.nih.gov/29514390
Publikováno v:
Hepatology (Baltimore, Md.). 69(2)
The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral treatment is not well documented. This study evaluated the impact of direct-acting antiviral-induced SVR on all-cause mortality and on incident hepatocellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b19e0c7b6b454ff4eeb699d6e1bfe0
https://pubmed.ncbi.nlm.nih.gov/28749564
https://pubmed.ncbi.nlm.nih.gov/28749564
Publikováno v:
Antiviral therapy. 22(6)
Background Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ±RBV) and ombi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbc0b4b4a6c4b2aa99d420973cbd6e7f
https://pubmed.ncbi.nlm.nih.gov/27934775
https://pubmed.ncbi.nlm.nih.gov/27934775